The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon, Mali, Chad and Republic of Congo) and determine their role in the evolution of the pandemic.
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon, Mali, Chad and Republic of Congo) and determine their role in the evolution of the pandemic. The research will combine retrospective and prospective approaches to determine the evolutionary dynamics of the virus since the start of the pandemic. It is planned to sequence the entire Spike protein gene for 1550 viruses and make 300 entire genomes. This work will be supplemented by antibody seroneutralization and respiratory transcriptomics tests, in order to estimate the immuno-virological response of the COVID-19 disease associated with the identified SARS-CoV-2 variants.
Study Type
OBSERVATIONAL
Enrollment
12,600
Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Centre de Référence pour les pathogènes émergents et réémergent
Bobo-Dioulasso, Burkina Faso
Centre Hospitalier Universitaire la Référence Nationale (CHU-RN)
N'Djamena, Chad
CIRBA
Abidjan, Côte d’Ivoire
Unité Mixte de Recherche CIRMF-SSM
Libreville, Gabon
Number of SARS-CoV-2 sequences generated partially and in whole genome
This outcome represent our main gaol and will include sequences that were partially generated in the Spike proteine and full genomes as well. Our current target is 1550 sequences.
Time frame: Through study completion, an average of 1 year.
Number of individuals tested positive for COVID-19
This outcome will be focused on the number of persons that will be tested positive for COVID-19 throughout the study, using SARS-CoV-2 rapid antigen tests. We planned to screen 12000 individuals overall in the six participating countries.
Time frame: Up to six months
Number of new SARS-CoV-2 variants identify
This outcome represents the number of new viruses that are identified at the end of the study and have not been reported previously.
Time frame: Through study completion, an average of 1 year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
SEREFO
Bamako, Mali
Laboratoire National de Santé Publique Brazzaville
Brazzaville, Republic of the Congo